The ESMO guideline strategy: an identity statement and reflections on improvement
G. Pentheroudakis(European Society for Medical Oncology), Andrés Cervantes(INCLIVA Health Research Institute), Fátima Cardoso(Breast Cancer Alliance), Alan Horwich(Institute of Cancer Research), Solange Peters(University Hospital of Lausanne), Nicholas Pavlidis(University of Ioannina), Rolf A. Stahel(International Breast Cancer Study Group), C. Sessa(Vita-Salute San Raffaele University), Dirk Arnold(Asklepios Klinik Altona)
Cited by 5
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k